Literature DB >> 1954072

Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose.

B Oosterhuis1, J H Jonkman, T Andersson, P B Zuiderwijk, J N Jedema.   

Abstract

1. The influence of multiple dose administration of omeprazole on the pharmacokinetics of oral digoxin was studied in 10 healthy male volunteers. 2. In a randomized two-way crossover design a single dose of 1 mg digoxin was administered either alone (control) or on day 8 of an 11 day course of omeprazole 20 mg once daily. 3. Plasma digoxin concentrations were measured over 96 h after digoxin administration with a [125I]-r.i.a. method. 4. On average, Cmax and AUC values for digoxin were approximately 10% higher and tmax tended to be shorter during the administration of omeprazole, while the elimination rate constant was unaffected. 5. The increase in AUC(0,96 h) was statistically significant (P less than 0.05), but within the accepted range for bioequivalence. In two subjects the increase was approximately 30%. 6. It is concluded that co-treatment with omeprazole causes a minor increase in the absorption of oral digoxin. The magnitude of this effect is not considered to be clinically relevant for the majority of patients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1954072      PMCID: PMC1368632          DOI: 10.1111/j.1365-2125.1991.tb03953.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  8 in total

1.  Dose-independent pharmacokinetics of digoxin in humans.

Authors:  H R Ochs; D J Greenblatt; G Bodem; J S Harmatz
Journal:  Am Heart J       Date:  1978-10       Impact factor: 4.749

2.  Pharmacokinetics and metabolism of digoxigenin-mono-digitoxoside in man.

Authors:  J Kuhlmann; U Abshagen; N Rietbrock
Journal:  Eur J Clin Pharmacol       Date:  1974       Impact factor: 2.953

3.  Comparison of digoxin with some digitoxin metabolites on cat heart lung preparation.

Authors:  H Böttcher; H Lüllmann; D Proppe
Journal:  Eur J Pharmacol       Date:  1973-04       Impact factor: 4.432

4.  Structure-activity correlation of the lethality and central effects of selected cardiac glycosides.

Authors:  G L Lage; J L Spratt
Journal:  J Pharmacol Exp Ther       Date:  1966-06       Impact factor: 4.030

5.  Single- and multiple-dose kinetics of intravenous digoxin.

Authors:  H R Ochs; D J Greenblatt; G Bodem
Journal:  Clin Pharmacol Ther       Date:  1980-09       Impact factor: 6.875

Review 6.  Pharmacokinetic interactions of cimetidine 1987.

Authors:  A Somogyi; M Muirhead
Journal:  Clin Pharmacokinet       Date:  1987-05       Impact factor: 6.447

7.  Influence of gastric pH on digoxin biotransformation. I. Intragastric hydrolysis.

Authors:  H Gault; J Kalra; M Ahmed; D Kepkay; J Barrowman
Journal:  Clin Pharmacol Ther       Date:  1980-01       Impact factor: 6.875

8.  Influence of gastric pH on digoxin biotransformation. II. Extractable urinary metabolites.

Authors:  H Gault; J Kalra; M Ahmed; D Kepkay; L Longerich; J Barrowman
Journal:  Clin Pharmacol Ther       Date:  1981-02       Impact factor: 6.875

  8 in total
  23 in total

Review 1.  Pharmacokinetic drug interaction profiles of proton pump inhibitors.

Authors:  Henning Blume; Frank Donath; André Warnke; Barbara S Schug
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

2.  Interaction risk with proton pump inhibitors in general practice: significant disagreement between different drug-related information sources.

Authors:  Gianluca Trifirò; Salvatore Corrao; Marianna Alacqua; Salvatore Moretti; Michele Tari; Achille P Caputi; Vincenzo Arcoraci
Journal:  Br J Clin Pharmacol       Date:  2006-07-06       Impact factor: 4.335

3.  Evaluation of felodipine as a potential perpetrator of pharmacokinetic drug-drug interactions.

Authors:  Ben D Snyder; Andrew Rowland; Thomas M Polasek; John O Miners; Matthew P Doogue
Journal:  Eur J Clin Pharmacol       Date:  2014-07-17       Impact factor: 2.953

4.  Safety and pharmacokinetics of the CIME combination of drugs and their metabolites after a single oral dosing in healthy volunteers.

Authors:  Natacha Lenuzza; Xavier Duval; Grégory Nicolas; Etienne Thévenot; Sylvie Job; Orianne Videau; Céline Narjoz; Marie-Anne Loriot; Philippe Beaune; Laurent Becquemont; France Mentré; Christian Funck-Brentano; Loubna Alavoine; Philippe Arnaud; Marcel Delaforge; Henri Bénech
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-12-03       Impact factor: 2.441

Review 5.  Pharmacokinetic considerations in the eradication of Helicobacter pylori.

Authors:  U Klotz
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

6.  Clarithromycin, Midazolam, and Digoxin: Application of PBPK Modeling to Gain New Insights into Drug-Drug Interactions and Co-medication Regimens.

Authors:  Daniel Moj; Nina Hanke; Hannah Britz; Sebastian Frechen; Tobias Kanacher; Thomas Wendl; Walter Emil Haefeli; Thorsten Lehr
Journal:  AAPS J       Date:  2016-11-07       Impact factor: 4.009

Review 7.  Proton Pump Inhibitors in the Elderly, Balancing Risk and Benefit: an Age-Old Problem.

Authors:  Takeshi Kanno; Paul Moayyedi
Journal:  Curr Gastroenterol Rep       Date:  2019-12-05

8.  Physiologically based pharmacokinetic modelling and in vivo [I]/K(i) accurately predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate.

Authors:  Yuansheng Zhao; Zhe-Yi Hu
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

9.  Omeprazole induces gastric permeability to digoxin.

Authors:  M Gabello; M C Valenzano; M Barr; P Zurbach; J M Mullin
Journal:  Dig Dis Sci       Date:  2009-06-10       Impact factor: 3.199

Review 10.  Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.

Authors:  T Andersson
Journal:  Clin Pharmacokinet       Date:  1996-07       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.